Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 5:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 2,126 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Colorectal cancer Clear all
Terminated Phase 2 Interventional Results available

Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment

NCT00538291
View directory record Official record
Conditions
Colorectal Cancer
Interventions
cetuximab, capecitabine, gene expression analysis, microarray analysis, polymorphism analysis, reverse transcriptase-polymerase chain reaction, immunohistochemistry staining method
Biological · Drug · Genetic + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Multilevel Intervention Based on Colorectal Cancer (CRC) and Cervical Cancer Self-screening in Rural, Segregated Areas

NCT04471194
View directory record Official record
Conditions
Colorectal Cancer Screening, Cervical Cancer Screening
Interventions
Self-sampling HPV test, Fecal occult blood test
Diagnostic Test
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
50 Years to 65 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Oct 14, 2026, 5:14 PM EDT
Recruiting Phase 1 Interventional

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

NCT06696768
View directory record Official record
Conditions
Metastatic Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Adenocarcinoma
Interventions
Bevacizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Emavusertib, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Oxaliplatin, Positron Emission Tomography
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
13
States / cities
Gainesville, Florida • Shiloh, Illinois • Fairway, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Phase 3 Interventional Results available

Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen

NCT00561470
View directory record Official record
Conditions
Colorectal Neoplasms, Neoplasm Metastasis
Interventions
Placebo, Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
87
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Hot Springs, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2012 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Adaptive Intervention to Maximize Colorectal Screening in Safety Net Populations

NCT03100461
View directory record Official record
Conditions
Colorectal Cancer
Interventions
I2, Health Education
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
50 Years to 75 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 14, 2026, 5:14 PM EDT
Recruiting Phase 1 Interventional

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

NCT06974110
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Endometrial Cancer, MSI-H Cancer, Colorectal Cancer, Gastric Cancer, dMMR Cancer
Interventions
MOMA-341, Irinotecan, Immunotherapy
Drug
Lead sponsor
MOMA Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Phoenix, Arizona • San Diego, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 14, 2026, 5:14 PM EDT
Terminated Phase 1 Interventional

Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus

NCT02283359
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Selinexor, Irinotecan
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 15, 2016 · Synced Oct 14, 2026, 5:14 PM EDT
Not listed No phase listed Observational

Expressive Disclosure and Colorectal Cancer

NCT00853203
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Interviews, Questionnaires, Electronically Activated Recorder (EAR), Group Meetings, Written Materials
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 14, 2026, 5:14 PM EDT
Terminated Phase 4 Interventional

Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6

NCT01468623
View directory record Official record
Conditions
Colorectal Cancer, Metastatic
Interventions
Pharmacokinetic 5-FU dose adjustment using OnDose® assay, Standard of care
Other
Lead sponsor
Myriad Genetic Laboratories, Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
58
States / cities
Birmingham, Alabama • Corona, California • Fountain Valley, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 14, 2026, 5:14 PM EDT
Terminated Phase 1 Interventional Results available

An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.

NCT03029988
View directory record Official record
Conditions
Liver Metastases, Colorectal Carcinoma
Interventions
Tilmanocept (Technetium Tc 99m tilmanocept Injection), SPECT/CT Imaging
Drug · Procedure
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Oct 14, 2026, 5:14 PM EDT
Recruiting Not applicable Interventional

Improving Uptake of Surveillance in Colorectal Cancer Survivors Through Navigation and Web Education

NCT06995924
View directory record Official record
Conditions
Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8
Interventions
Educational Intervention, Electronic Health Record Review, Internet-Based Intervention, Patient Navigation, Survey Administration
Other · Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 14, 2026, 5:14 PM EDT
Not listed Phase 1 Interventional

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

NCT05989724
View directory record Official record
Conditions
Solid Tumor, Breast Cancer, Pancreatic Cancer, Ovarian Cancer, Colorectal Cancer
Interventions
SON-DP
Drug
Lead sponsor
Qurgen Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Gilbert, Arizona • Detroit, Michigan • Huntersville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Not applicable Interventional Results available

Visualization of the Colon Through Use of the Magnetic Flexible Endoscope (MFE)

NCT05833789
View directory record Official record
Conditions
Colonoscopy
Interventions
Magnetic Flexible Endoscope (MFE)
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 14, 2026, 5:14 PM EDT
Terminated Phase 1 Interventional Results available

A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions

NCT04645797
View directory record Official record
Conditions
Advanced Colorectal Carcinoma
Interventions
APR003
Drug
Lead sponsor
Apros Therapeutics, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Orlando, Florida • Huntersville, North Carolina • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 14, 2026, 5:14 PM EDT
Terminated Not applicable Interventional Results available

A Study Assessing Perfusion Outcomes With PINPOINT® Near Infrared Fluorescence Imaging in Low Anterior Resection

NCT02205307
View directory record Official record
Conditions
Rectal Cancer, Rectosigmoid Cancer
Interventions
PINPOINT, SPY Elite
Device
Lead sponsor
Novadaq Technologies ULC, now a part of Stryker
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
24
States / cities
Concord, California • Los Angeles, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Phase 1 Interventional Results available

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

NCT01770353
View directory record Official record
Conditions
Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis
Interventions
Ferumoxytol, MM-398
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
7
States / cities
Scottsdale, Arizona • San Francisco, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 14, 2026, 5:14 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation

NCT06059963
View directory record Official record
Conditions
Colorectal Cancer, Advanced Adenocarcinoma
Interventions
Signal-C™
Device
Lead sponsor
Universal Diagnostics
Industry
Eligibility
45 Years to 84 Years
Enrollment
12,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Raonoke, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 14, 2026, 5:14 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

NCT04557449
View directory record Official record
Conditions
Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung
Interventions
PF-07220060, Letrozole, Fulvestrant, Midazolam, Enzalutamide
Drug · Combination Product
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
14
States / cities
Los Angeles, California • New Haven, Connecticut • Trumbull, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer

NCT02191761
View directory record Official record
Conditions
Colorectal Cancer, Gastric Cancer, Hepatic Cancer, Pancreatic Cancer
Interventions
SM04755
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Scottsdale, Arizona • La Jolla, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Not applicable Interventional

Default Genetics Referrals for Young-Onset Colorectal Cancer

NCT05018156
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Default Genetics Referral Process
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 49 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Oct 14, 2026, 5:14 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).

NCT04895722
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Pembrolizumab, Pembrolizumab/Quavonlimab, Pembrolizumab/Favezelimab, Pembrolizumab/Vibostolimab, MK-4830
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
11
States / cities
Orange City, Florida • Athens, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 14, 2026, 5:14 PM EDT
Terminated Phase 1 Interventional

Oral Green Tea Extract and Milk Thistle Extract to Colorectal Cancer Patients Undergoing Resection

NCT01239095
View directory record Official record
Conditions
Colon Cancer
Interventions
Green Tea and Milk Thistle Supplements
Drug
Lead sponsor
Richard Whelan
Other
Eligibility
18 Years to 85 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 14, 2026, 5:14 PM EDT
Recruiting Not applicable Interventional

BILe Acid-gut Microbiome Axis MODification Through Diet Education for Colorectal Cancer Prevention

NCT07162337
View directory record Official record
Conditions
Colorectal Cancer Prevention, Colorectal Adenoma
Interventions
Increased Plant-Based Diet and Decreased Animal-Based Diet
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma

NCT01394939
View directory record Official record
Conditions
Colorectal Carcinoma, CRC
Interventions
JX-594, Irinotecan
Biological · Drug
Lead sponsor
Jennerex Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
6
States / cities
Scottsdale, Arizona • La Jolla, California • Billings, Montana + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 14, 2026, 5:14 PM EDT